Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535826 | 0.95 | SLC6A3 (0.37) | SLC6A3BCHEHDAC1HDAC6TLR8 | |
| SCHEMBL5547243 | 0.94 | KCNH2 (0.39) | SLC6A3BCHEHDAC1HDAC6ADRB3 | |
| SCHEMBL5546523 | 0.82 | SLC6A3 (0.41) | SLC6A3BCHEHDAC1HDAC6ADRB3 | |
| SCHEMBL21699960 | 0.78 | SLC6A3 (0.52) | SLC6A3HDAC1HDAC6TLR8TLR7 | |
| SCHEMBL5539297 | 0.78 | SLC6A3 (0.41) | SLC6A3BCHE | |
| SCHEMBL7488547 | 0.77 | SLC6A3 (0.39) | SLC6A3BCHEHDAC1HDAC6TLR8 | |
| SCHEMBL12674305 | 0.77 | SLC6A3 (0.44) | SLC6A3HDAC1HDAC6TLR8TLR7 | |
| SCHEMBL25653945 | 0.75 | SLC6A3 (0.50) | SLC6A3HDAC1HDAC6TLR8TLR7 | |
| SCHEMBL5536462 | 0.74 | NOS1 (0.36) | — | |
| SCHEMBL27426865 | 0.74 | SLC6A3 (0.43) | SLC6A3HDAC1HDAC6TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SLC6A3 1944/4885BCHE 4833/4885HDAC1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.